Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 vs Immediate AlloHCT in High-Grade Myeloid Neoplasms with MRD
NCT04526288Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine in acute myeloid leukemia (AML), myelodysplastic syndrome with excess blasts-2 (MDS-EB-2), sponsored by Fred Hutchinson Cancer Center. Started Aug 2021; status: terminated.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)
Beyond the preview
Go deeper on NCT04526288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526288.